Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple blood test guide cancer treatment? new study investigates.

NCT ID NCT05032092

Knowledge-focused Sponsor: Medical University of Graz Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 2 times

Summary

This study looks at whether analyzing the genes of a tumor (from a tissue sample or a blood test) can help doctors pick a more effective treatment for people with advanced solid cancers that have stopped responding to standard therapies. About 235 participants will have their tumor DNA tested, and researchers will track how long their next treatment keeps the cancer from growing compared to their previous therapy. The goal is to see if this personalized approach improves outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

235 people

The number who actually took part.

Started

Nov 2021

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Initial diagnosis of histologically confirmed locally advanced and/or metastatic solid cancer * Radiologically confirmed progression under the most recent therapy * No further evidence-based drug treatment is established, or no satisfactory alternative treatments are available for the locally advanced and/or metastasized carcinoma * Further therapy is medically feasible * ECOG (Eastern Cooperative Oncology Group) performance status 0-2 * Life expectancy of at least 12 weeks * Written informed consent and willingness to cooperate during the course of the study * Capability to understand the intention and the consequences of the study Exclusion Criteria: * Untreated CNS (central nervous system) metastases. Patients with treated CNS metastases are eligible if they are clinically stable with regard to neurologic function * Pregnant or breast feeding * Other malignomas, diagnosed \< 5a before inclusion (except localized squamous cell carcinomas of the skin, surgically curable melanomas of the skin, basal cell carcinomas of the skin)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

carcinoma metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced carcinoma Metastatic cancer

Contacts and locations

Locations

  • Landesklinikum Amstetten

    Amstetten, 3300, Austria

  • Landeskrankenhaus Feldkirch, Department of Internal Medicine II

    Feldkirch, Vorarlberg, 6807, Austria

  • Medical University of Graz

    Graz, 8036, Austria

  • Medical University of Innsbruck, Department of Hematology and Oncology

    Innsbruck, Tyrol, 6020, Austria

  • Ordensklinikum Linz

    Linz, Upper Austria, 4010, Austria

  • University Hospital Salzburg, Department of Internal Medicine III

    Salzburg, State of Salzburg, 5020, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.